← Back

Wire · opportunities

Bausch + Lomb and Celldex rocked by respective phase 2 flops

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Celldex announced stopping development of barzolvolimab in atopic dermatitis after failing phase 2 endpoints despite some benefits, while Bausch + Lomb plans FDA discussions on phase 2 data for BL1332 in post-surgical ocular pain to explore alternative clinical measures for phase 3.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must prepare for tougher regulatory discussions on clinical endpoints in pain and skin conditions as FDA dialogues now value patient-meaningful measures over traditional endpoints. Celldex’s halt and Bausch + Lomb’s pivot show that close FDA engagement can keep programs alive despite phase 2 setbacks.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialsphase-2drug-developmentregulatory-engagementbiotech